Category - Developments

Developments

Arch announces non-brokered private placement

Arch BioPartners (TXSV:ARCH; QTCQB:ACHFF) has arranged a non-brokered private placement of 225,806 common shares at $1.55 per share, generating proceeds of CAD $350,000. According to Arch, the offering, set to close...

March 5, 2025

Developments

ASBrS selects Perimeter’s B-Series OCT with ImgAssist AI 2.0 pivotal trial results for presentation at 2025 annual meeting

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that detailed results from its pivotal trial evaluating the next-generation B-Series OCT with ImgAssist AI 2.0 for breast-conserving surgery (BCS) will be...

March 5, 2025

Developments

Stereotaxis submits EMAGIN robotic catheter for FDA clearance

Stereotaxis (NYSE:STXS) has announced that it has submitted its robotically navigated catheter, EMAGIN 5F, for FDA regulatory clearance. According to Sterotaxis, EMAGIN 5F, short for endovascular magnetic intervention...

March 3, 2025

Developments

Personalis spotlights new publication from ICR and Royal Marsden on ctDNA testing in MRD

Personalis (NASDAQ:PSNL) in collaboration with the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust, UK, has announced published results from its early-stage breast cancer study in...

March 3, 2025

Developments

Kairos presents positive preclinical outcomes of anti-tumor therapies at AACR IO

Kairos Pharma (NYSE:KAPA) announced the presentation of positive preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research and Immuno-Oncology (ACCR IO)...

February 26, 2025

Developments

Alligator reports encouraging OS for mitazalimab in metastatic pancreatic cancer

Alligator Bioscience (STO:ATORX) has announced updated results from its Phase 2 OPTIMIZE-1 study evaluating mitazalimab in combination with chemotherapy as a first-line treatment for metastatic pancreatic cancer...

February 26, 2025

Developments

IP highlights Istesso’s Phase 2b study findings of leramistat in RA

IP Group (LSE:IPO) has reported that Instesso has provided its shareholders with the results of its 12-week randomized, double-blind, placebo controlled Phase 2b study of leramistat in patients with moderate-to-severe...

February 25, 2025

Developments

First patient dosed in Aim’s Phase 2 study of Ampligen and Imfinzi in pancreatic cancer

AIM ImmunoTech (NYSE American:AIM) announced that the first new patient has been dosed in the Phase 2 study of its Ampligen and Astra Zeneca’s anti-PD-L1 immune checkpoint inhibitor, Imfinzi, as a potential combination...

February 25, 2025

Developments

OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) has announced that full efficacy and safety data from the induction period of the randomized, double-blind, placebo-controlled, Phase 2 CoTikiS study of...

February 24, 2025

Developments

PepGen reveals positive initial Phase 1 study results of PGN-EDODM1 in DM1

PepGen (NASDAQ:PEPG) has announced initial positive data from the five and ten mg/kg dose cohorts in its ongoing FREEDOM-DM1 Phase 1 study investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). PeoGen reports that...

February 24, 2025

Category - Developments

Subscribe